Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin

Pain Medicine (United States)

Volumn 16, Issue 10, 2015, Pages 2000-2011

  Freeman, Roy ^a   Wallace, Mark S ^b   Sweeney, Michael ^c   Backonja, Misha M ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c Depomed Inc   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Gabapentin; Gastroretentive; Neuropathic Pain; Pain Intensity; Pain Interference; Pain Quality; Postherpetic Neuralgia; Quality of Life

Indexed keywords

GABAPENTIN; PLACEBO; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DELAYED RELEASE FORMULATION;

ADULT; AGE DISTRIBUTION; AGED; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOOD; PAIN ASSESSMENT; PAIN INTENSITY; PHASE 3 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SLEEP QUALITY; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; AMINES; ANALGESICS; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84943665777     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12791     Document Type: Article

References (37)

1. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996;67:241-51.
2. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: Epidemiology, pathophysiology and management. Expert Rev Neurother 2007;7:1581-95.
3. Philip A, Thakur R. Post herpetic neuralgia. J Palliat Med 2011;14:765-73.
4. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37.
5. Harden RN, Kaye AD, Kintanar T, Argoff CE. Evidence-based guidance for the management of postherpetic neuralgia in primary care. Postgrad Med 2013;125:191-202.
6. Irving G. Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: An update for clinicians. Ther Adv Chronic Dis 2012;3:211-8.
7. Gordi T, Hou E, Kasichayanula S, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive, extended-release, and immediate-release tablets: A randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 2008;30:909-16.
8. Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: Comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 2011;51:346-58.
9. Sang CN, Sathyanarayana R, Sweeney M, Investigators DMS. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clin J Pain 2013;29:281-8.
10. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: A randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig 2010;30:765-76.
11. Rauck RL, Irving GA, Wallace MS, Vanhove GF, Sweeney M. Once-daily gastroretentive gabapentin for postherpetic neuralgia: Integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Pain Symptom Manage 2013;46:219-28.
12. Jensen MP. Review of measures of neuropathic pain. Curr Pain Headache Rep 2006;10:159-66.
13. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997;48:332-8.
14. Fishbain DA, Lewis JE, Cutler R, et al. Can the neuropathic pain scale discriminate between non-neuropathic and neuropathic pain? Pain Med 2008;9:149-60.
15. Jensen MP, Chiang YK, Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clin J Pain 2009;25:286-92.
16. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain 2006;22:97-103.
17. Jensen MP, Dworkin RH, Gammaitoni AR, et al. Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale. J Pain 2005;6:98-106.
18. Dworkin RH, Gnann JW Jr, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008;9:S37-44.
19. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
20. Dworkin RH, Jensen MP, Gammaitoni AR, Olaleye DO, Galer BS. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain 2007;8:118-26.
21. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 2005;29:401-10.
22. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. J Pain 2004;5:344-56.
23. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 2004;5:133-7.
24. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
25. Irving GA, Sweeney M. Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia. J Pain Res 2012;5:203-8.
26. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301.
27. Farrar JD, Young JPJ, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
28. Cheville AL, Sloan JA, Northfelt DW, et al. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: A phase III double-blind crossover study (N01CB). Support Care Cancer 2009;17:451-60.
29. Eardley W, Toth C. An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy. J Pain Res 2010;3:33-49.
30. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? Pain 2010;149:194-201.
31. Perez-Lloret S, Rojas GM, Menoni MC, et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. Clin Neuropharmacol 2012;35:21-4.
32. Nalamachu S, Bucior I. Randomized Controlled Trial versus Real-World Study in Postherpetic Neuralgia. J Pain Relief 2014;3:154.
33. Rice AS, Maton S. Postherpetic neuralgia study G. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
34. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998;280:1837-42.
35. Backonja MM, Stacey B. Neuropathic pain symptoms relative to overall pain rating. J Pain 2004;5:491-7.
36. Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain 2014;155:367-76.
37. Glauser TA, Salinas GD, Nevins H, et al. Communication gaps between physicians and patients with postherpetic neuralgia: Results from a national study on practice patterns. J Pain Res 2011;4:407-15.